PT-141
Bremelanotide — Melanocortin Receptor Agonist
What is PT-141?
PT-141 (Bremelanotide) is a synthetic melanocortin peptide acting centrally on MC3R and MC4R receptors to increase sexual desire and arousal. It is the first FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi.
Unlike PDE5 inhibitors which work peripherally through vascular mechanisms, PT-141 acts centrally in the hypothalamus and limbic system to increase dopamine activity and sexual motivation — making it effective for both men and women, including cases where psychological or neurological factors contribute.
Research Evidence
Phase 3 trials supporting FDA approval demonstrated significant improvement in satisfying sexual events and desire scores vs placebo in premenopausal women with HSDD.
Phase 2 trials showed dose-dependent improvements in erectile response, including in patients who did not respond to PDE5 inhibitors.
Evidence grades: Gold = RCT human data · Silver = multiple animal studies, consistent · Bronze = limited or preliminary
Dosing Protocols
Reconstitution Guide
| Vial Size | BAC Water | Concentration | Target draw |
|---|---|---|---|
| 2 mg | 1 ml | 2 mg/ml | 1mg = 50 units |
| 10 mg | 5 ml | 2 mg/ml | 1mg = 50 units |
Frequently Asked Questions
Does PT-141 work for men?
Yes. Though FDA-approved only for women, PT-141 has Phase 2 clinical trial data in men showing significant improvements in erectile function, including in men who did not respond to PDE5 inhibitors. It works centrally through dopaminergic activation rather than peripheral vascular effects.
What are the main side effects of PT-141?
Flushing (transient facial redness and warmth) occurs in 40-60% of users. Nausea is the second most common effect, particularly at higher doses. Both typically peak 30-90 minutes post-injection and resolve within a few hours.
References
- [1]Diamond LE, Earle DC, Heiman JR, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141). J Sex Med. 2006;3(4):628-638.
- [2]U.S. Food & Drug Administration. Vyleesi (bremelanotide) prescribing information. AMAG Pharmaceuticals. 2019.
This profile was prepared using AI-assisted research synthesis. Citations are provided where applicable — verify with primary sources before clinical application.
Share this article